{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:40:36Z","timestamp":1783021236419,"version":"3.54.6"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP200668"],"award-info":[{"award-number":["RP200668"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["BAO19XX0"],"award-info":[{"award-number":["BAO19XX0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["BAO19XX1"],"award-info":[{"award-number":["BAO19XX1"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jcf.2024.07.001","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T11:54:12Z","timestamp":1721994852000},"page":"716-724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cystic fibrosis cell models for high-throughput analysis and drug screening"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5574-195X","authenticated-orcid":false,"given":"Aidi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6672-3470","authenticated-orcid":false,"given":"Mithil","family":"Chokshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nghi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid T.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford C.","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5501-554X","authenticated-orcid":false,"given":"Gang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.07.001_bib0001","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.07.001_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR Modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2024.07.001_bib0003","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jcf.2024.07.001_bib0004","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.07.001_bib0005","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ame2.12180","article-title":"A review of cystic fibrosis: basic and clinical aspects","volume":"4","author":"Chen","year":"2021","journal-title":"Animal Model Exp Med"},{"key":"10.1016\/j.jcf.2024.07.001_bib0006","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0092-8674(90)90148-8","article-title":"Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis","volume":"63","author":"Cheng","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.jcf.2024.07.001_bib0007","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/358761a0","article-title":"Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive","volume":"358","author":"Denning","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.jcf.2024.07.001_bib0008","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/jmg.2006.045880","article-title":"Exon skipping through the creation of a putative exonic splicing silencer as a consequence of the cystic fibrosis mutation R553X","volume":"44","author":"Aznarez","year":"2007","journal-title":"J Med Genet"},{"key":"10.1016\/j.jcf.2024.07.001_bib0009","first-page":"22","article-title":"Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene","author":"Venturini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2024.07.001_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041335","article-title":"Mechanisms and regulation of nonsense-mediated mRNA decay and nonsense-associated altered splicing in lymphocytes","volume":"21","author":"Lambert","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2024.07.001_bib0011","first-page":"e16144","article-title":"A review of trikafta: triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator therapy","volume":"13","author":"Zaher","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.jcf.2024.07.001_bib0012","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.07.001_bib0013","first-page":"1","article-title":"The U.S. Food and Drug Administration's experience with ivacaftor in cystic fibrosis. Establishing efficacy using in vitro data in lieu of a clinical trial","volume":"15","author":"Durmowicz","year":"2018"},{"key":"10.1016\/j.jcf.2024.07.001_bib0014","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1165\/ajrcmb.10.1.7507342","article-title":"CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells","volume":"10","author":"Cozens","year":"1994","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2024.07.001_bib0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajpath.2020.10.017","article-title":"Animal and cell culture models for cystic fibrosis: which model is right for your application?","volume":"191","author":"McCarron","year":"2021","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jcf.2024.07.001_bib0016","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jcf.2017.09.001","article-title":"Animal and model systems for studying cystic fibrosis","volume":"17","author":"Rosen","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.07.001_bib0017","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"Dekkers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jcf.2024.07.001_bib0018","doi-asserted-by":"crossref","first-page":"37235","DOI":"10.1074\/jbc.M205932200","article-title":"High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening","volume":"277","author":"Ma","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcf.2024.07.001_bib0019","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1172\/JCI24898","article-title":"Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening","volume":"115","author":"Pedemonte","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2024.07.001_bib0020","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3389\/fphar.2018.01221","article-title":"Identification and characterization of Novel CFTR potentiators","volume":"9","author":"Gees","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2024.07.001_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030754","article-title":"Phenotyping of rare CFTR mutations reveals distinct trafficking and functional defects","volume":"9","author":"Ensinck","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jcf.2024.07.001_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191618","article-title":"Assessment of p.Phe508del-CFTR functional restoration in pediatric primary cystic fibrosis airway epithelial cells","volume":"13","author":"Sutanto","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2024.07.001_bib0023","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2472555217729790","article-title":"Use of a high-throughput phenotypic screening strategy to identify amplifiers, a novel pharmacological class of small molecules that exhibit functional synergy with potentiators and correctors","volume":"23","author":"Giuliano","year":"2018","journal-title":"SLAS Discov"},{"key":"10.1016\/j.jcf.2024.07.001_bib0024","article-title":"Potentiation of \u0394F508- and G551D-CFTR-Mediated Cl- current by novel hydroxypyrazolines","volume":"11","author":"Park","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2024.07.001_bib0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00018-016-2391-y","article-title":"Role of CFTR in epithelial physiology","volume":"74","author":"Saint-Criq","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jcf.2024.07.001_bib0026","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0014-5793(01)02561-3","article-title":"Green fluorescent protein-based halide indicators with improved chloride and iodide affinities","volume":"499","author":"Galietta","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jcf.2024.07.001_bib0027","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygeno.2008.09.014","article-title":"Next generation tools for high-throughput promoter and expression analysis employing single-copy knock-ins at the Hprt1 locus","volume":"93","author":"Yang","year":"2009","journal-title":"Genomics"},{"key":"10.1016\/j.jcf.2024.07.001_bib0028","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1152\/physiolgenomics.90328.2008","article-title":"Targeted transgenesis at the HPRT locus: an efficient strategy to achieve tightly controlled in vivo conditional expression with the tet system","volume":"37","author":"Palais","year":"2009","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.jcf.2024.07.001_bib0029","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41525-017-0015-6","article-title":"Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia","volume":"2","author":"Ahmadi","year":"2017","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.jcf.2024.07.001_bib0030","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1165\/rcmb.2018-0316OC","article-title":"Nonsense-mediated RNA decay pathway inhibition restores expression and function of W1282X CFTR","volume":"61","author":"Keenan","year":"2019","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2024.07.001_bib0031","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1085\/jgp.200609667","article-title":"G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects","volume":"129","author":"Bompadre","year":"2007","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.jcf.2024.07.001_bib0032","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1074\/jbc.M709417200","article-title":"Mechanism of G551D-CFTR (cystic fibrosis transmembrane conductance regulator) potentiation by a high affinity ATP analog","volume":"283","author":"Bompadre","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcf.2024.07.001_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13010102","article-title":"Additive potentiation of R334W-CFTR function by novel small molecules","volume":"13","author":"Bacalhau","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.jcf.2024.07.001_bib0034","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Fredrick","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.07.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54158-2","article-title":"Nanomolar-potency \u2018co-potentiator\u2019 therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants","volume":"9","author":"Phuan PT","year":"2019","journal-title":"Scientific reports"},{"key":"10.1016\/j.jcf.2024.07.001_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1155705","article-title":"Personalized medicine: Function of CFTR variant p.Arg334Trp is rescued by currently available CFTR modulators","volume":"10","author":"Railean","year":"2023","journal-title":"Frontiers in Molecular Biosciences"},{"key":"10.1016\/j.jcf.2024.07.001_bib0037","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2018.12.001","article-title":"Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells","volume":"18","author":"Valley","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.07.001_bib0038","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1006\/geno.1994.1070","article-title":"The stop mutation R553X in the CFTR gene results in exon skipping","volume":"19","author":"Hull","year":"1994","journal-title":"Genomincs"},{"key":"10.1016\/j.jcf.2024.07.001_bib0039","doi-asserted-by":"crossref","first-page":"19723","DOI":"10.1074\/jbc.M101892200","article-title":"Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds","volume":"276","author":"Galietta","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcf.2024.07.001_bib0040","doi-asserted-by":"crossref","first-page":"C1734","DOI":"10.1152\/ajpcell.2001.281.5.C1734","article-title":"Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists","volume":"281","author":"Galietta","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jcf.2024.07.001_bib0041","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1089\/adt.2010.0312","article-title":"Optimization of a Yellow fluorescent protein-based iodide influx high-throughput screening assay for cystic fibrosis transmembrane conductance regulator (CFTR) modulators","volume":"8","author":"Sui","year":"2010","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.jcf.2024.07.001_bib0042","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.stemcr.2021.09.020","article-title":"A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients","volume":"16","author":"Jiang","year":"2021","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.jcf.2024.07.001_bib0043","series-title":"Primary epithelial cell models for cystic fibrosis research","author":"Randell","year":"2011"},{"key":"10.1016\/j.jcf.2024.07.001_bib0044","series-title":"Human Nasal and Tracheo-Bronchial respiratory epithelial cell culture","author":"Fulcher","year":"2012"},{"key":"10.1016\/j.jcf.2024.07.001_bib0045","first-page":"134","article-title":"Generation of human nasal epithelial cell spheroids for individualized cystic fibrosis transmembrane conductance regulator study","author":"Brewington","year":"2018","journal-title":"Journal of Visualized Experiments"},{"key":"10.1016\/j.jcf.2024.07.001_bib0046","article-title":"Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies","volume":"3","author":"Brewington","year":"2018","journal-title":"Journal of Clinical Investigation Insight"},{"key":"10.1016\/j.jcf.2024.07.001_bib0047","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1164\/rccm.201808-1436LE","article-title":"Might brushed nasal cells be a surrogate for CFTR modulator clinical response?","volume":"199","author":"Pranke","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324007884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324007884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:08:06Z","timestamp":1783019286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324007884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1569199324007884"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.07.001","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystic fibrosis cell models for high-throughput analysis and drug screening","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}